Abstract
Human immunodeficiency virus (HIV) infection first manifested itself as Acquired Immune Deficiency Syndrome (AIDS) in the early 1980s when young, previously healthy homosexual men presented with Pneumocystis carinii pneumonia (PCP). Since the discovery of HIV and AIDS, many different respiratory infections (common, uncommon and opportunistic), as well as different malignancies such as Kaposis sarcoma, and destructive lung processes, such as emphysema have been shown to occur more commonly in the setting of HIV. Alterations in the CD4+/CD8+ lymphocyte composition and changes in the function of B cells compromise host defenses and predispose an HIV infected individual to respiratory infections. Highly Active Antiretroviral Therapy (HAART) has dramatically altered the course of HIV infection through suppression of viral replication, a reconstitution of CD4+ cells, and the resultant decrease in opportunistic infections, including PCP. This manuscript provides a contemporary review of the respiratory diseases of patients with HIV.
Keywords: Pneumocystis carinii pneumonia (PCP), (HAART), cytomegalovirus infections, lower lung diffusing capacity (DLCO), tuberculosis (TB), Mini-Bronchoalveolar Lavage, Kaposi's Sarcoma, Lymphoma, Immunocompetence
Current Respiratory Medicine Reviews
Title: HIV and Respiratory Disease: A Contemporary Perspective
Volume: 1 Issue: 3
Author(s): Albert E. Holt IV, Wendy Turenne and Anthony D. Slonim
Affiliation:
Keywords: Pneumocystis carinii pneumonia (PCP), (HAART), cytomegalovirus infections, lower lung diffusing capacity (DLCO), tuberculosis (TB), Mini-Bronchoalveolar Lavage, Kaposi's Sarcoma, Lymphoma, Immunocompetence
Abstract: Human immunodeficiency virus (HIV) infection first manifested itself as Acquired Immune Deficiency Syndrome (AIDS) in the early 1980s when young, previously healthy homosexual men presented with Pneumocystis carinii pneumonia (PCP). Since the discovery of HIV and AIDS, many different respiratory infections (common, uncommon and opportunistic), as well as different malignancies such as Kaposis sarcoma, and destructive lung processes, such as emphysema have been shown to occur more commonly in the setting of HIV. Alterations in the CD4+/CD8+ lymphocyte composition and changes in the function of B cells compromise host defenses and predispose an HIV infected individual to respiratory infections. Highly Active Antiretroviral Therapy (HAART) has dramatically altered the course of HIV infection through suppression of viral replication, a reconstitution of CD4+ cells, and the resultant decrease in opportunistic infections, including PCP. This manuscript provides a contemporary review of the respiratory diseases of patients with HIV.
Export Options
About this article
Cite this article as:
Holt IV E. Albert, Turenne Wendy and Slonim D. Anthony, HIV and Respiratory Disease: A Contemporary Perspective, Current Respiratory Medicine Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339805774597947
DOI https://dx.doi.org/10.2174/157339805774597947 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dequalinium-Derived Nanoconstructs: A Promising Vehicle for Mitochondrial Targeting
Current Drug Delivery Supramolecular Nanomedicine - An Overview
Current Drug Targets Abscopal Effect of Radiation Therapy and Signal Transduction
Current Signal Transduction Therapy Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Anlotinib-Induced Hypertension: Current Concepts and Future Prospects
Current Pharmaceutical Design Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Protein-Protein Interactions and Cancer: Targeting the Central Dogma
Current Topics in Medicinal Chemistry Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets Melphalan in Regional Chemotherapy for Locally Recurrent Metastatic Melanoma
Current Topics in Medicinal Chemistry Targeted Therapy in Advanced Gastric Carcinoma: The Future is Beginning
Current Medicinal Chemistry Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design Editorial
Recent Patents on Anti-Cancer Drug Discovery The Imaging of Apoptosis with the Radiolabelled Annexin A5: A New Tool in Translational Research
Current Clinical Pharmacology Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design